AAM Names Teva’s Baeder Chair As It Kicks Off Annual Meeting
Interim CEO David Gaugh Acknowledged That Members Currently Face ‘Pain And Uncertainty’
Executive Summary
Christine Baeder has become chair of the AAM’s board, with the Teva executive welcomed to role as the US industry association kicked off its annual Access! conference in Orlando.
You may also be interested in...
AAM Departures Lead To Change Of Chair For IGBA
The AAM has confirmed the departure of three executives, one of whom had also been serving as chair of the IGBA. As a result, the global generics industry association has brought in a new interim chair, at the same time as the head of one of the industry’s largest players has joined its CEO Advisory Committee.
AAM Warns Over Biden Budget Plans To Extend IRA
US generics and biosimilars association the AAM has offered a frosty response to budget plans announced by the Biden administration that include expanding the scope of price negotiation under the Inflation Reduction Act.
‘Disruptor’ Mark Cuban Takes Aim At US Industry Barriers
During a lively discussion at the AAM’s Access! conference in Orlando, billionaire entrepreneur Mark Cuban set out how he plans to use his Cost Plus Drugs company to disrupt the generics sector while also lifting its reputation by increasing trust and transparency among patients.